• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Merkel cell carcinoma in collision with squamous cell carcinoma and basal cell carcinoma in a patient on ruxolitinib treatment for myeloproliferative neoplasm.

作者信息

Barrera-Penagos Viviana, Castellanos-Leguizamón Daniela, Hakim-Tawil José Antonio, Santivañez Juan José, Rodríguez-Urrego Paula A, Hiromi López-Takegami Juan Carlos

机构信息

Department of Pathology and Laboratories, Fundación Santa Fe de Bogotá, Bogotá D.C., Colombia.

Division of Head and Neck Surgery, Fundación Santa Fe de Bogotá, Bogotá D.C., Colombia.

出版信息

JAAD Case Rep. 2024 Feb 2;45:98-101. doi: 10.1016/j.jdcr.2024.01.024. eCollection 2024 Mar.

DOI:10.1016/j.jdcr.2024.01.024
PMID:38434601
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10907503/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfad/10907503/60ca77bca42d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfad/10907503/498b27b583d1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfad/10907503/6835a5f4a037/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfad/10907503/60ca77bca42d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfad/10907503/498b27b583d1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfad/10907503/6835a5f4a037/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bfad/10907503/60ca77bca42d/gr3.jpg

相似文献

1
Merkel cell carcinoma in collision with squamous cell carcinoma and basal cell carcinoma in a patient on ruxolitinib treatment for myeloproliferative neoplasm.一名接受鲁索替尼治疗骨髓增殖性肿瘤的患者发生 Merkel 细胞癌，并与鳞状细胞癌和基底细胞癌碰撞。
JAAD Case Rep. 2024 Feb 2;45:98-101. doi: 10.1016/j.jdcr.2024.01.024. eCollection 2024 Mar.
2
Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis.Janus激酶抑制剂相关的皮肤癌：世界卫生组织药物安全数据库分析
Therapie. 2022 Nov-Dec;77(6):649-656. doi: 10.1016/j.therap.2022.04.005. Epub 2022 May 7.
3
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.接受 Janus 激酶抑制剂芦可替尼治疗真性红细胞增多症后出现侵袭性 Merkel 细胞癌。
In Vivo. 2019 Sep-Oct;33(5):1667-1669. doi: 10.21873/invivo.11653.
4
Increased Risk of Keratinocyte Carcinomas, Merkel Cell Carcinoma, and Other Skin Cancers in Patients Treated With Janus Kinase 1 and 2 Inhibitor, Ruxolitinib.使用Janus激酶1和2抑制剂鲁索替尼治疗的患者发生角质形成细胞癌、默克尔细胞癌和其他皮肤癌的风险增加。
J Cutan Med Surg. 2024 Sep-Oct;28(5):486-487. doi: 10.1177/12034754241258364. Epub 2024 Jun 10.
5
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.一名正在使用Janus激酶抑制剂鲁索替尼的患者发生侵袭性鳞状细胞癌。
JAAD Case Rep. 2018 Apr 30;4(5):455-457. doi: 10.1016/j.jdcr.2018.01.001. eCollection 2018 Jun.
6
Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma.芦可替尼与阿维鲁单抗联合治疗默克尔细胞癌期间的血液学毒性
Front Oncol. 2020 Oct 22;10:579914. doi: 10.3389/fonc.2020.579914. eCollection 2020.
7
Triple collision tumor comprising Merkel cell carcinoma with an unusual immunophenotype, squamous cell carcinoma in situ, and basal cell carcinoma.三重碰撞肿瘤，包含具有不寻常免疫表型的 Merkel 细胞癌、原位鳞状细胞癌和基底细胞癌。
J Cutan Pathol. 2020 Aug;47(8):764-767. doi: 10.1111/cup.13698. Epub 2020 May 13.
8
Combined Merkel Cell Carcinoma and Squamous Cell Carcinoma: A Systematic Review.默克尔细胞癌与鳞状细胞癌合并：一项系统综述。
Cancers (Basel). 2024 Jan 18;16(2):411. doi: 10.3390/cancers16020411.
9
Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).伴嗜酸粒细胞增多的骨髓增生性肿瘤伴 t(8;9)(p21;p24)易位患者对芦可替尼的持续缓解。
Acta Haematol. 2023;146(5):397-400. doi: 10.1159/000510281. Epub 2023 Aug 10.
10
Merkel Cell Polyomavirus‒Negative Merkel Cell Carcinoma Originating from In Situ Squamous Cell Carcinoma: A Keratinocytic Tumor with Neuroendocrine Differentiation.源自原位鳞状细胞癌的默克尔细胞多瘤病毒阴性默克尔细胞癌：一种具有神经内分泌分化的角质形成细胞肿瘤
J Invest Dermatol. 2022 Mar;142(3 Pt A):516-527. doi: 10.1016/j.jid.2021.07.175. Epub 2021 Sep 1.

本文引用的文献

1
A review on the oncogenesis of Merkel cell carcinoma: Several subsets arise from different stages of differentiation of stem cell.默克尔细胞癌的发生机制研究进展：多个亚群起源于干细胞分化的不同阶段。
Medicine (Baltimore). 2023 Apr 14;102(15):e33535. doi: 10.1097/MD.0000000000033535.
2
Janus Kinase Inhibitors and Non-Melanoma Skin Cancer.Janus 激酶抑制剂与非黑素瘤皮肤癌。
Curr Treat Options Oncol. 2021 Jan 9;22(2):11. doi: 10.1007/s11864-020-00815-y.
3
Immunotherapy in Myeloproliferative Diseases.免疫疗法在骨髓增殖性疾病中的应用。
Cells. 2020 Jun 26;9(6):1559. doi: 10.3390/cells9061559.
4
Actinic Keratosis Diagnosis and Increased Risk of Developing Skin Cancer: A 10-year Cohort Study of 17,651 Patients in Sweden.光化性角化病的诊断与皮肤癌发病风险增加：瑞典一项纳入 17651 例患者的长达 10 年的队列研究。
Acta Derm Venereol. 2020 Apr 29;100(8):adv00128. doi: 10.2340/00015555-3486.
5
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.接受 Janus 激酶抑制剂芦可替尼治疗真性红细胞增多症后出现侵袭性 Merkel 细胞癌。
In Vivo. 2019 Sep-Oct;33(5):1667-1669. doi: 10.21873/invivo.11653.
6
A case of combined Merkel cell carcinoma and squamous cell carcinoma: Molecular insights and diagnostic pitfalls.一例默克尔细胞癌与鳞状细胞癌合并病例：分子学见解与诊断陷阱
JAAD Case Rep. 2018 Nov 3;4(10):996-999. doi: 10.1016/j.jdcr.2018.08.004. eCollection 2018 Nov.
7
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.一名正在使用Janus激酶抑制剂鲁索替尼的患者发生侵袭性鳞状细胞癌。
JAAD Case Rep. 2018 Apr 30;4(5):455-457. doi: 10.1016/j.jdcr.2018.01.001. eCollection 2018 Jun.
8
Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib.接受JAK激酶抑制剂鲁索替尼治疗的患者发生侵袭性皮肤癌。
J Drugs Dermatol. 2017 May 1;16(5):508-511.
9
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.COMFORT-II的长期研究结果，这是一项关于芦可替尼与最佳可用疗法治疗骨髓纤维化的3期研究。
Leukemia. 2016 Aug;30(8):1701-7. doi: 10.1038/leu.2016.148. Epub 2016 May 23.